Monalizumab是一种人源化单克隆抗体类免疫检查点抑制剂，其作用靶点为自然杀伤细胞表面受体 NKG2A，通过阻断 NKG2A 介导的抑制性信号，可增强自然杀伤细胞的功能并促进干扰素-γ（IFN-γ）的生成。

Purity:SDS-PAGE

Anti-NKG2A / CD94 Reference Antibody (monalizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.

Purity:SEC-HPLC

The purity of Anti-NKG2A / CD94 Reference Antibody (monalizumab) is more than 95%, determined by SEC-HPLC.

Bioactivity:FACS

Human NKG2A/CD94 HEK293 cells were stained with Anti-NKG2A / CD94 Reference Antibody (monalizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.0409 ug/mL.

Function:Blocking

Anti-NKG2A / CD159a Reference Antibody (monalizumab) FACS Blocking was evaluated using human NKG2A/CD94 HEK293 cells. The IC50 was approximately 0.2162 nM.

Function:Luciferase

Anti-NKG2A / CD159a Reference Antibody (monalizumab) Luciferase Assay was evaluated using Human NKG2A/CD94 HEK293. The EC50 was approximately 0.5236 nM.

-25~-15℃保存，有效期1年。